Premium
Different effects of metoclopramide and domperidone on arginine‐ vasopressin secretion in man.
Author(s) -
Chiodera P,
Volpi R,
Delsignore R,
Marchesi C,
Salati G,
Camellini L,
Rossi G,
Coiro V
Publication year - 1986
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1986.tb02921.x
Subject(s) - domperidone , metoclopramide , vasopressin , dopaminergic , endocrinology , medicine , dopamine antagonist , dopamine , dopamine receptor , antagonist , vasopressin receptor , arginine , receptor , chemistry , biochemistry , amino acid , vomiting
This study was performed in order to investigate the dopaminergic mechanism involved in the control of arginine‐vasopressin (AVP) secretion in normal men. Plasma AVP concentrations were measured before and after the administration of an i.v. bolus of 10 mg metoclopramide or domperidone to twelve healthy males. Metoclopramide, a cerebral and peripheral antagonist of dopaminergic receptors, significantly stimulated AVP secretion, whereas domperidone, a dopamine antagonist which does not cross the blood‐brain barrier, was without effect. These data suggest that metoclopramide stimulates the release of AVP by blocking dopaminergic receptors in structures located inside the blood‐ brain barrier. Alternatively, it is possible that the stimulation of AVP release induced by metoclopramide does not occur through inhibition of dopamine receptors but rather through interaction with other neuroendocrine pathways.